Genetically engineered drugs for treatment of bronchial asthma: Recent achievements

Current population of patients with asthma is characterized by increasing resistance to standard pharmacotherapeutic agents such as inhaled corticosteroids, antileukotriene agents and anti-IgE antibodies. These findings were confirmed by international statistic data and indicate insufficient efficacy of the treatment. Asthma phenotyping encompassing a role of certain biomarkers for bronchial inflammation could contribute to achieving better response to treatment. Genetically engineered drugs could directly impact on mediators and modulators involved in the inflammation and bronchoconstriction. This is one of the most promising directions of the modern pharmacotherapy, particularly considering severe and difficult-to-treat asthma. A comparative analysis of efficacy and safety of currently available genetically engineered drug groups (monoclonal anti-IgE antibodies, monoclonal antibodies against interleukin (IL)-4/IL-13 and IL-5, and prostaglandin D2 receptor antagonists) was performed by the authors of this article on the basis of results of randomized controlled clinical trials (RCT). According to RCT results, omalizumab is still the leading genetically engineered drug. Moreover, evidence of efficacy and safety of novel agents has been published that allowed implementation these drugs in the routine clinical practice for treatment of severe eosinophilic asthma. © 2019 American Psychiatric Association. All rights reserved.

Авторы
Редакторы
-
Журнал
Издательство
Medical Education
Номер выпуска
5
Язык
Русский
Страницы
584-601
Статус
Опубликовано
Подразделение
-
Номер
-
Том
28
Год
2018
Организации
  • 1 The Peoples' Friendship University of Russia, Medical University, ul. Miklukho-Maklaya 6, Moscow, 117198, Russian Federation
  • 2 Moscow State Educational Government-Financed Institution, City Clinical Hospital No.24, Department of Health Care of the City of Moscow, ul. Pistsovaya 10, Moscow, 127015, Russian Federation
Ключевые слова
Benralizumab; Bronchial asthma; Dupilumab; Fevipiprant; Genetically engineered drugs; Humanized monoclonal antibodies; Lebrikizumab; Ligelizumab; Mepolizumab; Omalizumab; Phenotypes of bronchial asthma; Quilizumab; Tralokinumab
Дата создания
04.02.2019
Дата изменения
04.02.2019
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/36450/